Clinical Trials Logo

NK/T-cell Lymphoma clinical trials

View clinical trials related to NK/T-cell Lymphoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04230330 Withdrawn - NK/T Cell Lymphoma Clinical Trials

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Start date: December 12, 2019
Phase: Phase 1
Study type: Interventional

This is a pilot study investigating the role of nivolumab, a PD-1 inhibitor, in the treatment of advanced stage or relapsed/refractory NKTL. Patients who have received PD-1 inhibitors will be excluded from this study. Patients who have a complete response or good partial response to nivolumab during initial phase will continue to be treated with nivolumab. Patients who have a partial response, stable disease, and progressive disease to nivolumab during initial phase will be treated with the combination of nivolumab and GDP/L-asparaginase.